JP2018519245A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519245A5 JP2018519245A5 JP2017551628A JP2017551628A JP2018519245A5 JP 2018519245 A5 JP2018519245 A5 JP 2018519245A5 JP 2017551628 A JP2017551628 A JP 2017551628A JP 2017551628 A JP2017551628 A JP 2017551628A JP 2018519245 A5 JP2018519245 A5 JP 2018519245A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- compound according
- heterocyclyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562142589P | 2015-04-03 | 2015-04-03 | |
| US62/142,589 | 2015-04-03 | ||
| PCT/US2016/025544 WO2016161279A1 (en) | 2015-04-03 | 2016-04-01 | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018519245A JP2018519245A (ja) | 2018-07-19 |
| JP2018519245A5 true JP2018519245A5 (enExample) | 2019-05-09 |
Family
ID=55702190
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017551647A Pending JP2018516238A (ja) | 2015-04-03 | 2016-04-01 | 癌の治療のためのインドールアミン−２，３−ジオキシゲナーゼの阻害剤およびそれらの使用方法 |
| JP2017551628A Withdrawn JP2018519245A (ja) | 2015-04-03 | 2016-04-01 | 癌の治療のためのインドールアミン−２，３−ジオキシゲナーゼの阻害剤およびそれらの使用方法 |
| JP2017551629A Withdrawn JP2018515438A (ja) | 2015-04-03 | 2016-04-01 | 癌の治療のためのインドールアミン−２，３−ジオキシゲナーゼの阻害剤およびそれらの使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017551647A Pending JP2018516238A (ja) | 2015-04-03 | 2016-04-01 | 癌の治療のためのインドールアミン−２，３−ジオキシゲナーゼの阻害剤およびそれらの使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017551629A Withdrawn JP2018515438A (ja) | 2015-04-03 | 2016-04-01 | 癌の治療のためのインドールアミン−２，３−ジオキシゲナーゼの阻害剤およびそれらの使用方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10399933B2 (enExample) |
| EP (3) | EP3277671A1 (enExample) |
| JP (3) | JP2018516238A (enExample) |
| KR (3) | KR20170136557A (enExample) |
| CN (3) | CN107743490A (enExample) |
| AR (1) | AR104176A1 (enExample) |
| AU (3) | AU2016242978A1 (enExample) |
| BR (3) | BR112017020895A2 (enExample) |
| CA (3) | CA2981660A1 (enExample) |
| CL (1) | CL2017002494A1 (enExample) |
| CO (1) | CO2017011183A2 (enExample) |
| EA (3) | EA201792186A1 (enExample) |
| HK (1) | HK1247922A1 (enExample) |
| IL (3) | IL254722A0 (enExample) |
| MX (3) | MX2017012738A (enExample) |
| PE (1) | PE20180117A1 (enExample) |
| SG (3) | SG11201807980QA (enExample) |
| TW (1) | TW201700453A (enExample) |
| UY (1) | UY36601A (enExample) |
| WO (3) | WO2016161279A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| TWI664164B (zh) | 2014-02-13 | 2019-07-01 | 美商英塞特控股公司 | 作為ｌｓｄ１抑制劑之環丙胺 |
| PE20161573A1 (es) | 2014-02-13 | 2017-01-19 | Incyte Corp | Ciclopropilamina como inhibidor de la lsd1 |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| US9695168B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors |
| US10399933B2 (en) * | 2015-04-03 | 2019-09-03 | Bristol-Myers Squibb Company | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer |
| MY191796A (en) | 2015-04-03 | 2022-07-15 | Incyte Corp | Heterocyclic compounds as lsd1 inhibitors |
| KR102710120B1 (ko) | 2015-08-12 | 2024-09-27 | 인사이트 홀딩스 코포레이션 | Lsd1 저해제의 염 |
| CN108368049A (zh) * | 2015-09-24 | 2018-08-03 | 葛兰素史克知识产权开发有限公司 | 吲哚胺2,3-双加氧酶的调节剂 |
| EP3558978A1 (en) * | 2016-12-20 | 2019-10-30 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
| WO2018116108A1 (en) * | 2016-12-20 | 2018-06-28 | Glaxosmithkline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
| PE20191541A1 (es) | 2016-12-22 | 2019-10-23 | Calithera Biosciences Inc | Composiciones y metodos para inhibir la accion de la arginasa |
| JP2020506895A (ja) | 2017-01-17 | 2020-03-05 | ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | インドールアミン２，３−ジオキシゲナーゼおよび／またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物 |
| US20200188482A1 (en) * | 2017-04-28 | 2020-06-18 | The Brigham And Women`S Hospital, Inc. | Targeting gamma-delta t cells in obesity and cachexia |
| WO2018204532A1 (en) | 2017-05-03 | 2018-11-08 | Vivace Therapeutics, Inc. | Non-fused tricyclic compounds |
| US11370762B2 (en) * | 2017-06-02 | 2022-06-28 | Shenyang Research Institute Of Chemical Industry Co., Ltd. | Vinylarene derivative and application |
| CN110785408A (zh) * | 2017-06-28 | 2020-02-11 | 葛兰素史克知识产权开发有限公司 | 吲哚胺2,3-双加氧酶的调节剂 |
| CN107325019B (zh) * | 2017-08-11 | 2019-11-22 | 石河子大学 | 芳胺基苯甲酰胺类化合物及n-芳基-芳胺基苯甲酰胺类化合物的制备方法 |
| JP7245229B2 (ja) | 2017-08-21 | 2023-03-23 | ビバーチェ セラピューティクス，インク． | ベンゾスルホニル化合物 |
| WO2019078968A2 (en) * | 2017-10-18 | 2019-04-25 | Angex Pharmaceutical, Inc. | CYCLIC COMPOUNDS AS IMMUNOMODULATORS |
| CN109836356B (zh) * | 2017-11-24 | 2022-03-08 | 沈阳化工研究院有限公司 | 一种芳甲醚衍生物及其应用 |
| EP3720430A4 (en) | 2017-12-06 | 2021-05-05 | Vivace Therapeutics, Inc. | BENZOCARBONYL COMPOUNDS |
| CN111587116A (zh) | 2018-01-05 | 2020-08-25 | 迪克纳制药公司 | 降低β-连环蛋白和IDO表达以加强免疫疗法 |
| US11447449B2 (en) | 2018-01-05 | 2022-09-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| EP3793551A4 (en) | 2018-05-16 | 2022-01-26 | Vivace Therapeutics, Inc. | OXADIAZOLE COMPOUNDS |
| WO2020010223A1 (en) * | 2018-07-06 | 2020-01-09 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| US11046649B2 (en) | 2018-07-17 | 2021-06-29 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| WO2020023355A1 (en) * | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| CN109608334B (zh) * | 2019-01-11 | 2021-07-13 | 盐城通海生物科技有限公司 | 一种合成4-甲氧基巴豆酸甲酯的方法 |
| EP3917963A1 (en) * | 2019-02-01 | 2021-12-08 | GlaxoSmithKline Intellectual Property Development Limited | Belantamab mafodotin in combination with pembrolizumab for treating cancer |
| KR102386849B1 (ko) * | 2019-10-14 | 2022-04-13 | 포항공과대학교 산학협력단 | 면역치료를 위한 환경 반응형 접착성 항체전달체 및 이의 제조방법 |
| WO2021102618A1 (en) * | 2019-11-25 | 2021-06-03 | InventisBio Co., Ltd. | Novel salts of indoleamine 2,3-dioxygenase inhibitors |
| CN113214138A (zh) * | 2020-02-04 | 2021-08-06 | 中国医学科学院药物研究所 | 苯丙酸类衍生物、及其制法和药物组合物与用途 |
| US11839659B2 (en) | 2020-07-02 | 2023-12-12 | Northwestern University | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein |
| CN112174891B (zh) * | 2020-11-02 | 2022-02-01 | 浙江省农业科学院 | 一种氟唑菌苯胺代谢物的制备方法 |
| JP2024016314A (ja) * | 2020-12-24 | 2024-02-07 | 小野薬品工業株式会社 | 一般式（ｉ－ａ）で示される化合物、その薬学的に許容される塩、またはそれらの水和物と免疫チェックポイント阻害薬および／またはｅｐ４受容体拮抗薬との組み合わせ |
| US20240091202A1 (en) | 2021-03-05 | 2024-03-21 | Universität Basel | Compositions for the treatment of ebv associated diseases or conditions |
| EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3622337A (en) * | 1968-08-02 | 1971-11-23 | Gaf Corp | Cyan color formers for color photography |
| US4252894A (en) * | 1975-10-22 | 1981-02-24 | Gaf Corporation | Hydrophilic color coupler composition containing diepoxide |
| US7312214B2 (en) | 2002-05-10 | 2007-12-25 | Bristol-Myers Squibb Company | 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors |
| EP1663953A1 (en) | 2003-09-24 | 2006-06-07 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| CN1882529A (zh) * | 2003-09-24 | 2006-12-20 | 梅特希尔基因公司 | 组蛋白脱乙酰基酶抑制剂 |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| DK1866339T3 (da) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
| DK2559690T3 (en) | 2005-05-10 | 2016-04-25 | Incyte Holdings Corp | Modulators of indoleamine 2,3-dioxygenase and methods of use thereof |
| HRP20151102T1 (xx) | 2005-07-01 | 2015-11-20 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1) |
| ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| CN101426774B (zh) * | 2006-04-19 | 2012-04-25 | 安斯泰来制药有限公司 | 唑类甲酰胺衍生物 |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| US20080125470A1 (en) | 2006-09-19 | 2008-05-29 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| CA2932121A1 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics Corporation | Ido inhibitors |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| KR20250091300A (ko) | 2008-12-09 | 2025-06-20 | 제넨테크, 인크. | 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도 |
| CN103951753B (zh) | 2009-09-03 | 2018-01-12 | 默沙东公司 | 抗‑gitr抗体 |
| ES2601226T3 (es) | 2009-10-28 | 2017-02-14 | Newlink Genetics Corporation | Derivados de imidazol como inhibidores de IDO |
| CN105218672A (zh) | 2009-12-10 | 2016-01-06 | 霍夫曼-拉罗奇有限公司 | 优先结合人csf1r胞外域4的抗体及其用途 |
| ME03447B (me) | 2010-03-04 | 2020-01-20 | Macrogenics Inc | Anтitela reakтivna sa b7-нз, njihovi imunološki akтivni fragmenтi i upotreba |
| KR101656548B1 (ko) | 2010-03-05 | 2016-09-09 | 에프. 호프만-라 로슈 아게 | 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도 |
| RU2617966C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| KR20200044999A (ko) | 2010-05-04 | 2020-04-29 | 파이브 프라임 테라퓨틱스, 인크. | Ｃｓｆ1ｒ에 결합하는 항체들 |
| CN105481983B (zh) | 2010-09-09 | 2021-09-03 | 辉瑞公司 | 4-1bb结合分子 |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| MX338353B (es) | 2011-04-20 | 2016-04-13 | Medimmune Llc | Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1. |
| SMT202000561T1 (it) | 2011-11-28 | 2021-01-05 | Merck Patent Gmbh | Anticorpi anti-pd-l1 e usi relativi |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| JP6416630B2 (ja) | 2012-02-06 | 2018-10-31 | ジェネンテック， インコーポレイテッド | Ｃｓｆ１ｒ阻害剤を用いるための組成物及び方法 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| EP2847220A1 (en) | 2012-05-11 | 2015-03-18 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| TWI713436B (zh) | 2012-08-31 | 2020-12-21 | 美商戊瑞治療有限公司 | 用結合群落刺激因子１受體（ｃｓｆ１ｒ）之抗體治療病狀之方法 |
| MA38483A1 (fr) * | 2013-03-15 | 2018-02-28 | Bristol Myers Squibb Co | Inhibiteurs de l'ido |
| BR112015021999A8 (pt) * | 2013-03-15 | 2019-12-03 | Bristol Myers Squibb Co | inibidores de indoleamina 2,3-dioxigenase (ido), seus usos, composição farmacêutica, e método para inibir a atiavidade de indoleamina 2,3-dioxigenase |
| WO2015031295A1 (en) * | 2013-08-27 | 2015-03-05 | Bristol-Myers Squibb Company | Ido inhibitors |
| US10399933B2 (en) * | 2015-04-03 | 2019-09-03 | Bristol-Myers Squibb Company | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer |
-
2016
- 2016-04-01 US US15/564,153 patent/US10399933B2/en active Active
- 2016-04-01 CN CN201680032158.4A patent/CN107743490A/zh active Pending
- 2016-04-01 KR KR1020177031542A patent/KR20170136557A/ko not_active Withdrawn
- 2016-04-01 BR BR112017020895A patent/BR112017020895A2/pt not_active Application Discontinuation
- 2016-04-01 CN CN201680032165.4A patent/CN108093636A/zh active Pending
- 2016-04-01 SG SG11201807980QA patent/SG11201807980QA/en unknown
- 2016-04-01 EP EP16715778.3A patent/EP3277671A1/en not_active Withdrawn
- 2016-04-01 AU AU2016242978A patent/AU2016242978A1/en not_active Abandoned
- 2016-04-01 AU AU2016243937A patent/AU2016243937A1/en not_active Abandoned
- 2016-04-01 KR KR1020177031598A patent/KR20170134981A/ko not_active Withdrawn
- 2016-04-01 BR BR112017021021A patent/BR112017021021A2/pt not_active Application Discontinuation
- 2016-04-01 US US15/088,211 patent/US9790169B2/en active Active
- 2016-04-01 WO PCT/US2016/025544 patent/WO2016161279A1/en not_active Ceased
- 2016-04-01 UY UY0001036601A patent/UY36601A/es unknown
- 2016-04-01 TW TW105110690A patent/TW201700453A/zh unknown
- 2016-04-01 EA EA201792186A patent/EA201792186A1/ru unknown
- 2016-04-01 US US15/564,146 patent/US10399932B2/en active Active
- 2016-04-01 EA EA201792231A patent/EA033395B1/ru not_active IP Right Cessation
- 2016-04-01 AR ARP160100897A patent/AR104176A1/es unknown
- 2016-04-01 WO PCT/US2016/025554 patent/WO2016161286A1/en not_active Ceased
- 2016-04-01 EA EA201792204A patent/EA201792204A1/ru unknown
- 2016-04-01 BR BR112017020999A patent/BR112017020999A2/pt not_active Application Discontinuation
- 2016-04-01 WO PCT/US2016/025531 patent/WO2016161269A1/en not_active Ceased
- 2016-04-01 SG SG11201707948WA patent/SG11201707948WA/en unknown
- 2016-04-01 MX MX2017012738A patent/MX2017012738A/es unknown
- 2016-04-01 MX MX2017012729A patent/MX2017012729A/es unknown
- 2016-04-01 KR KR1020177031596A patent/KR20170134980A/ko not_active Withdrawn
- 2016-04-01 CN CN201680032102.9A patent/CN107743481A/zh active Pending
- 2016-04-01 CA CA2981660A patent/CA2981660A1/en not_active Abandoned
- 2016-04-01 JP JP2017551647A patent/JP2018516238A/ja active Pending
- 2016-04-01 JP JP2017551628A patent/JP2018519245A/ja not_active Withdrawn
- 2016-04-01 PE PE2017001828A patent/PE20180117A1/es unknown
- 2016-04-01 SG SG11201708097SA patent/SG11201708097SA/en unknown
- 2016-04-01 CA CA2981584A patent/CA2981584A1/en not_active Abandoned
- 2016-04-01 CA CA2981657A patent/CA2981657A1/en not_active Abandoned
- 2016-04-01 JP JP2017551629A patent/JP2018515438A/ja not_active Withdrawn
- 2016-04-01 AU AU2016242973A patent/AU2016242973A1/en not_active Abandoned
- 2016-04-01 EP EP16715779.1A patent/EP3277672A1/en not_active Withdrawn
- 2016-04-01 MX MX2017012730A patent/MX2017012730A/es unknown
- 2016-04-01 HK HK18107390.1A patent/HK1247922A1/zh unknown
- 2016-04-01 EP EP16715777.5A patent/EP3277670A1/en not_active Withdrawn
-
2017
- 2017-05-02 US US15/584,818 patent/US10167254B2/en active Active
- 2017-09-26 IL IL254722A patent/IL254722A0/en unknown
- 2017-09-26 IL IL254719A patent/IL254719A0/en unknown
- 2017-09-26 IL IL254720A patent/IL254720A0/en unknown
- 2017-10-03 CL CL2017002494A patent/CL2017002494A1/es unknown
- 2017-10-31 CO CONC2017/0011183A patent/CO2017011183A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519245A5 (enExample) | ||
| JP2018516238A5 (enExample) | ||
| JP2018515438A5 (enExample) | ||
| JP2016528197A5 (enExample) | ||
| JP2020517616A5 (enExample) | ||
| JP2019529484A5 (enExample) | ||
| JP2016518324A5 (enExample) | ||
| JP2017537080A5 (enExample) | ||
| JP2013056930A5 (enExample) | ||
| JP2014525438A5 (enExample) | ||
| JP2016503799A5 (enExample) | ||
| JP2014508804A5 (enExample) | ||
| JP2014518544A5 (enExample) | ||
| JP2017509689A5 (enExample) | ||
| JP2016536286A5 (enExample) | ||
| JP2017528498A5 (enExample) | ||
| JP2017502940A5 (enExample) | ||
| JP2015503625A5 (enExample) | ||
| RU2017111200A (ru) | Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака | |
| JP2019524883A5 (enExample) | ||
| JP2016513660A5 (enExample) | ||
| JP2020507566A5 (enExample) | ||
| JP2017537940A5 (enExample) | ||
| JP2013510123A5 (enExample) | ||
| JP2015511609A5 (enExample) |